Global NSCLC Market Insights Forecasts to 2030
- The NSCLC market was valued at USD 16.1 Billion in 2021.
- The Market is Growing at a CAGR of 10.4% from 2022 to 2030
- The Global NSCLC Market is expected to reach USD 38.8 Billion by 2030
- Asia Pacific is expected to grow the fastest during the forecast period
Get more details on this report -
The Global NSCLC market is expected to reach USD 38.8 Billion by 2030, at a CAGR of 10.4% during the forecast period 2022 to 2030.
The most typical form of lung cancer is non-small cell lung carcinoma (NSCLC), also referred to as non-small cell lung cancer. The description "non-small cell" describes how cancer cells seem under a microscope. The moniker "small cell lung cancer" refers to the size of the cancer cells (SCLC). NSCLC has a greater survival rate than SCLC and is less likely to spread. The majority of patients with early-stage NSCLC live for at least five years, but if the cancer has already spread to other tissues when they are diagnosed, their chances of surviving are significantly lower.Another common kind of non-small cell lung cancer that is mostly brought on by tobacco use is squamous cell carcinoma. It primarily affects the middle of the lungs, which is close to the major airway. Because it can develop in any section of the lung and spreads more quickly than the other two, large cell carcinoma can be more difficult to cure.
This research report categorizes the market for NSCLC market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the NSCLC market. Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segments of the NSCLC market.
Global NSCLC Market Report Coverage
|Market Size in 2021:||USD 16.1 Billion|
|Forecast Period 2021-2030 CAGR:||10.4%|
|2030 Value Projection:||USD 38.8 Billion|
|Historical Data for:||2017-2020|
|No. of Pages:||190|
|Tables, Charts & Figures:||135|
|Segments covered:||By Type, By Treatment Type, By Distribution Channel, By Region, and COVID-19 Impact Analysis|
|Companies Covered:||F. Hoffmann-La Roche Ltd. (Switzerland), Mylan N.V. (U.S.), Teva Pharmaceutical Industries Ltd.(Israel), Sanofi (France), Pfizer Inc. (U.S.), GSK plc (U.K.), Novartis AG (Switzerland), Bayer AG (Germany), Lilly (U.S.), Merck & Co., Inc. (U.S.), Sun Pharmaceutical Industries Ltd. (India), Aurobindo Pharma (India), Lupin (India), CLOVIS ONCOLOGY (U.S.), Johnson & Johnson Private Limited (U.S.)|
|Growth Drivers:||Throughout the projection period, the global non-small cell lung cancer market will grow due to the rise in cancer cases worldwide.|
|Pitfalls & Challenges:||Recent market developments and competitive strategies such as expansion, product launch and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market.|
Get more details on this report -
Throughout the projection period, the global non-small cell lung cancer market will grow due to the rise in cancer cases worldwide. The bulk of SCLC cases, which have an annual death rate of 30,000, are found in patients between the ages of 60 and 80, according to American Cancer Society data from 2016. Additionally, 1.59 million people died from lung cancer in 2012, making it the second most frequent malignancy in both men and women. This promotes market expansion.Early-stage small cell lung cancer patients receive therapies like chemotherapy and radiation therapy. They offer patients a number of important benefits. Patients may receive radiation therapy, for instance, to reduce tumour cells and alleviate symptoms including coughing, difficulty swallowing, bleeding, and shortness of breath. Intensity modulated radiation therapy (IMRT) and three-dimensional conformal radiation therapy (3D-CRT) are two prevalent radiation treatment modalities.Patients and healthcare professionals are becoming increasingly aware of the prevalence of small cell lung cancer (SCLC). Now more than ever, both patients and physicians are actively learning about the medications available to treat these serious diseases. This is one of the most crucial market drivers. The market's opportunities are increased by this.
The development of the worldwide non-small cell lung cancer market during the forecast period may be constrained by a lack of skilled experts who are not familiar with the disease's treatment options.
- In 2021, the Adenocarcinoma segment holds the largest market share over the forecast period.
On the basis of type, the global NSCLC Market is segmented into Adenocarcinoma, Squamous Cell Carcinoma, Large Cell Carcinoma, Others. Among these, the adenocarcinoma segment holds the largest market share over the forecast period because adenocarcinoma affects a high number of patients, and because a wide range of treatments are available for this indication. During the projection period, the squamous cell carcinoma segment is anticipated to post a higher CAGR. For instance, the American Gastroenterological Society estimates that in 2020, there will be 604,100 new cases of esophageal cancer.
- In 2021, the Targeted Therapy segment is dominating the market over the forecast period.
Based on the treatment, the global NSCLC Market is segmented into Chemotherapy, Targeted Therapy, Immunotherapy. Among these, the targeted therapy segment is dominating the market over the forecast period owing to specific clinical advantages that this therapy offers, such as its low risk of adverse effects and the availability of numerous targeted medicines. Also, more patients are choosing targeted therapy as a cancer treatment option because it is effective in up to 80% of cases. The immunotherapy segment, on the other hand, is anticipated to experience significant market growth.
- In 2021, the Hospital Pharmacy segment is dominating the market over the forecast period.
On the basis of distribution channel, the global NSCLC Market is segmented into Hospital Pharmacy, Drug Store and Retail Pharmacy, Online Pharmacy. Among these, the hospital pharmacy segment is dominating the market over the forecast period. The dominance is caused by a growth in the number of NSCLC patients being admitted to hospitals and the presence of qualified specialists in these settings.
Regional Segment Analysis of the NSCLC Market
- North America (U.S., Canada, Mexico)
- Europe (Germany, France, U.K., Italy, Spain, Rest of Europe)
- Asia-Pacific (China, Japan, India, Rest of APAC)
- South America (Brazil and the Rest of South America)
- The Middle East and Africa (UAE, South Africa, Rest of MEA)
Get more details on this report -
North America is dominating the market with the largest market share over the forecast period.
In 2021, the non-small cell lung cancer market in North America held a leading position in terms of market share. This was due to the region's strong concentration of major companies, well-developed healthcare infrastructure, and increased public awareness of the importance of early cancer detection.The market is expanding due to the presence of several significant players in the area. Also, a rise in the number of people concerned with living a healthy lifestyle and a rise in the need for non-small cell lung cancer therapies in the area are anticipated to fuel market expansion. Moreover, a strong healthcare infrastructure and a rise in the use of various medicines for non-small cell lung cancer are anticipated to fuel market expansion.
- In May 2021, in order to expand its product lineup, Roche announced that the European Commission had approved Tecentriq. Adults with metastatic non-small cell lung cancer were treated with Tecentriq as their first line of defence.
The report offers the appropriate analysis of the key organizations/companies involved within the global NSCLC market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
List of Key Companies
- F. Hoffmann-La Roche Ltd. (Switzerland),
- Mylan N.V. (U.S.),
- Teva Pharmaceutical Industries Ltd.(Israel),
- Sanofi (France),
- Pfizer Inc. (U.S.),
- GSK plc (U.K.),
- Novartis AG (Switzerland),
- Bayer AG (Germany),
- Lilly (U.S.),
- Merck & Co., Inc. (U.S.),
- Sun Pharmaceutical Industries Ltd. (India),
- Aurobindo Pharma (India),
- Lupin (India),
- CLOVIS ONCOLOGY (U.S.),
- Johnson & Johnson Private Limited (U.S.)
Key Target Audience
- Market Players
- Government Authorities
- Consulting And Research Firm
- Venture capitalists
- Value-Added Resellers (VARs)
This study forecasts revenue at global, regional, and country levels from 2019 to 2030. Spherical Insights has segmented the global NSCLC market based on the below-mentioned segments:
NSCLC Market, By Type
- Squamous Cell Carcinoma
- Large Cell Carcinoma
NSCLC Market, By Treatment
- Targeted Therapy
NSCLC Market, By Distribution Channel
- Hospital Pharmacy
- Drug Store and Retail Pharmacy
- Online Pharmacy
NSCLC Market, Regional Analysis
- North America
- Rest of Europe
- Asia Pacific
- South Korea
- Rest of Asia Pacific
- South America
- Rest of South America
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Need help to buy this report?